Prosecution Insights
Last updated: November 20, 2026
Application No. 18/584,298

3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS

Final Rejection §102§112
Filed
Feb 22, 2024
Priority
Aug 24, 2021 — CN PCT/CN2021/114320 +2 more
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Genentech Inc.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
864 granted / 1271 resolved
+8.0% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
76 currently pending
Career history
1356
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
17.5%
-22.5% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
40.3%
+0.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1271 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is a Final Office Action. Claims 1-11, 14, 15, 17-19, 21-25 and 28-30 are pending and under consideration. Specification The objection to the abstract of the disclosure is withdrawn based on the amendments.. Claim Objections The objection to claim 1 because of the phrase, “C1-4 alkyl amino di(C1-4 alkyl)amino” is missing a comma between the two groups, see the definition of R7, is withdrawn based on the amendments. The objection to claims 12 and 16 because of the phrase, “any one of” is withdrawn based on the amendments. Claim 1 is objected to because of the following informalities: the phrase, “C1-4 alkyl amino di(C1-4 alkyl)amino” is missing a comma between the two groups, see the definition of Re and Rf, page 4 of 18. Appropriate correction is required. Claim 1 is objected to because of the following informalities: the formula is blurry and should be replaced. Appropriate correction is required. Claim 28 is objected to because of the following informalities: the phrase “in need thereof” is needed after the term “person” in said claim. Claims 21 and 23 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 The rejection of claim 16 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for the term “trifluoromethyl” is withdrawn based on the amendments. The rejection of claim 12 under 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for the term “halo” is withdrawn based on the amendments. The rejection of claims 25-27 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating pain and pruritus; and a method of decreasing ion flux through a voltage-dependent sodium channel, does not reasonably provide enablement for a method of treating cardiovascular diseases, respiratory diseases, psychiatric diseases or cancer generally, is withdrawn based on the amendments. The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 1, the phrase “methyl or ethyl substituted by phenyl” is ambiguous and vague. Does the claim encompass methyl not substituted with phenyl? Or is methyl and ethyl substituted with phenyl? Any dependent claim that does not address the deficiency is also rejected. Thus, claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected. The following is a quotation of the fourth paragraph of 35 U.S.C. 112: Subject to the [fifth paragraph of 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 22 is rejected under 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The term “cyclobutyl” in claim 22 does not further limit and is broader than claim 1, in the definition of R8. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. The rejection may be overcome by replacing with F, Cl, Br and I. The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. The definition of R8 has been amended to include 2,3-dihydro-1H-indenyl and pyridyl. It is noted that there are species with indenyl and pyridyl rings at R8. However, the amended genus is not supported by the disclosure. Thus, claims 1-11, 14, 15, 17-19, 24, 25 and 28-30are rejected. Claim Rejections - 35 USC § 102 The rejection of claims 1, 2, 12 and 24-28 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Brand et al. (US 20110312921), is withdrawn based on the amendments. The rejection of claims 1-3, 5-8, 10, 12, 13, 18 and 24 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Wilson et al. (US 20110082117), is withdrawn based on the amendments. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Feb 22, 2024
Application Filed
Mar 24, 2026
Non-Final Rejection mailed — §102, §112
Aug 24, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799096
HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS
3y 8m to grant Granted Nov 17, 2026
Patent 12782368
CHEMILUMINESCENT ANDROSTENEDIONE CONJUGATES
7y 2m to grant Granted Nov 03, 2026
Patent 12767658
TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF
4y 6m to grant Granted Oct 20, 2026
Patent 12760059
GLUCOCORTICOID RECEPTOR MODULATORS
3y 11m to grant Granted Oct 13, 2026
Patent 12753202
ANDROGEN RECEPTOR MODULATORS
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+31.6%)
2y 11m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1271 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month